trending Market Intelligence /marketintelligence/en/news-insights/trending/rgdTEQ0RmU6qVVXfUfSzIw2 content esgSubNav
In This List

BioMarin to sell priority review voucher for $125M

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


BioMarin to sell priority review voucher for $125M

BioMarin Pharmaceutical Inc. is selling a rare pediatric disease priority review voucher it received in April from the U.S. Food and Drug Administration for a lump sum payment of $125 million.

The company received the voucher after the approval of Brineura, a new biological product for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease.

The U.S. FDA awards the vouchers to rare pediatric disease product applicants that meet certain criteria. The voucher can be redeemed to receive a priority review of a subsequent marketing application for a different product.

BioMarin sold a priority review voucher to Regeneron Pharmaceuticals Inc. for $67.5 million in July 2014. The U.S. FDA awarded the voucher to BioMarin with the approval of Vimizim, for the treatment of Morquio A syndrome.